Dr. David Adelstein, MD of Cleveland Clinic discusses what is the optimal primary therapeutic option for patients with early stage or locally advanced carcinomas at the ASTRO Head and Neck Symposium 2016.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content